Market Overview

The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors


The Medicines Company (NASDAQ:MDCO) today announced that its Board of
Directors has appointed Dr. Sarah Schlesinger as a new, independent
Director of the Company, effective immediately.

Dr. Schlesinger has spent more than 20 years working in the field of
cellular immunity. She is currently the Chair of The Rockefeller
University Hospital's Institutional Review Board (IRB) and Senior
Physician and Associate Professor of Clinical Investigation at The
Rockefeller University. Prior to becoming Chair of the hospital's IRB,
Dr. Schlesinger served as Clinical Director of the Laboratory of
Molecular Immunology and Clinical Director of The Laboratory of Cellular
Immunology and Physiology – the laboratory led by the late Ralph M.
Steinman, M.D., 2011 Nobel Laureate in Physiology or Medicine. Before
joining The Rockefeller University in 2003, Dr. Schlesinger was a
scientist at the International AIDS Vaccine Initiative in New York City
from 2002 to 2003, and a Research Physician/Pathologist at the Division
of Retrovirology at the Walter Reed Army Institute of Research from 1996
to 2002. Dr. Schlesinger leads clinical trials and also chairs the
research education and training committee of the Center for Clinical and
Translational Science at The Rockefeller University Hospital. She is
co-director of Rockefeller's Clinical Scholars program and the
Certificate in Clinical and Translational Sciences program. Widely
published in her field, Dr. Schlesinger has been recognized with
numerous awards for her research and teaching. She is also a member of
numerous, prominent medical societies, including the United States and
Canadian Academy of Pathology, the American Association for the
Advancement of Science and the College of American Pathologists. Dr.
Schlesinger serves on the board of three non-profit organizations: AVAC
(AIDS Vaccines Advocacy Coalition); Global Viral; and The Hastings
Center, the pre-eminent center for the study of bioethics. She served as
an independent director of Ariad Pharmaceuticals from 2013 until its
sale to Takeda in 2017. She is currently a member of the Scientific
Advisory Board of Lycera Corp., as well as a consultant to Lycera's CEO
on matters of clinical development, and an independent director of
Innoviva Inc.

"We are pleased to welcome Sarah as a new, independent director of The
Medicines Company's Board of Directors," said Chief Executive Officer,
Clive Meanwell, M.D., Ph.D. "Sarah is a valuable addition as we continue
to successfully execute on our strategic plan. I know that the Company
will benefit from her expertise, insight and experience, and I and the
rest of the Board look forward to working with her."

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an
overriding purpose - to save lives, alleviate suffering and contribute
to the economics of healthcare. The Company's mission is to create
transformational solutions to address the most pressing healthcare needs
facing patients, physicians and providers in cardiovascular care. The
Company is headquartered in Parsippany, New Jersey.

View Comments and Join the Discussion!